Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs
- PMID: 20384585
- DOI: 10.2174/138920010791110836
Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs
Abstract
Oral delivery remains the preferred route for chronic drug administration thanks to its patient convenience and compliance. However, many drug candidates are unsuitable for conventional oral formulations due to low solubility, poor membrane permeability, or extensive pre-systemic metabolism. This review describes a promising strategy that incorporates or encapsulates the molecules with biodegradable and biocompatible nanoparticulate carriers. The entrapped drug substances can be protected against degradation by gastrointestinal fluids, while drug absorption through the gastrointestinal epithelium or lymphatic transport can be enhanced. Possible mechanisms for transport of these nanocarriers across gastrointestinal mucosa are introduced that focus on effects of size and surface properties of the nanocarriers on the non-specific or targeted uptake by enterocytes and/or M cells. Applications of various oral nanocarrier formulations, such as lipid nanoparticles, nanoemulsions and chitosan nanoparticles, are reviewed. Nanoparticulate drug carriers show great potential for improving the bioavailability of orally administered drugs.
Similar articles
-
Nanocarriers protecting toward an intestinal pre-uptake metabolism.Nanomedicine (Lond). 2017 Feb;12(3):255-269. doi: 10.2217/nnm-2016-0331. Epub 2017 Jan 17. Nanomedicine (Lond). 2017. PMID: 28093952 Review.
-
Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.Int J Pharm. 2015 Nov 10;495(1):9-18. doi: 10.1016/j.ijpharm.2015.08.086. Epub 2015 Sep 4. Int J Pharm. 2015. PMID: 26325310
-
Oral delivery of proteins by biodegradable nanoparticles.Adv Drug Deliv Rev. 2013 Jun 15;65(6):811-21. doi: 10.1016/j.addr.2013.04.006. Epub 2013 Apr 20. Adv Drug Deliv Rev. 2013. PMID: 23608641 Review.
-
[Oral bioavailability and drug/carrier particulate systems].Med Sci (Paris). 2008 Jun-Jul;24(6-7):659-64. doi: 10.1051/medsci/20082467659. Med Sci (Paris). 2008. PMID: 18601886 French.
-
Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.Curr Pharm Biotechnol. 2021;22(7):892-905. doi: 10.2174/1389201021666200804155535. Curr Pharm Biotechnol. 2021. PMID: 32753006 Review.
Cited by
-
Enhancement of the Bioavailability and Anti-Inflammatory Activity of Glycyrrhetinic Acid via Novel Soluplus®-A Glycyrrhetinic Acid Solid Dispersion.Pharmaceutics. 2022 Aug 26;14(9):1797. doi: 10.3390/pharmaceutics14091797. Pharmaceutics. 2022. PMID: 36145545 Free PMC article.
-
Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.J Control Release. 2012 Oct 10;163(1):25-33. doi: 10.1016/j.jconrel.2012.06.007. Epub 2012 Jun 12. J Control Release. 2012. PMID: 22698938 Free PMC article.
-
Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.Drug Deliv Transl Res. 2017 Apr;7(2):292-303. doi: 10.1007/s13346-016-0355-2. Drug Deliv Transl Res. 2017. PMID: 28116656
-
Revitalizing Vision: Eye Drops and Corneal Limbal Stem Cells Survival.Stem Cell Rev Rep. 2025 Apr;21(3):730-743. doi: 10.1007/s12015-025-10841-8. Epub 2025 Jan 9. Stem Cell Rev Rep. 2025. PMID: 39786675 Review.
-
Evidence of oral translocation of anionic G6.5 dendrimers in mice.Mol Pharm. 2013 Mar 4;10(3):988-98. doi: 10.1021/mp300436c. Epub 2013 Jan 25. Mol Pharm. 2013. PMID: 23286733 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical